THERAPEUTIC INTERACTIONS OF LEUKOMETHYLTHIONINIUM Russian patent published in 2025 - IPC A61K31/13 A61K31/27 A61K31/445 A61K31/5415 A61K31/55 A61K45/06 A61P25/28 

FIELD: chemistry; pharmaceutics.

SUBSTANCE: group of inventions relates to pharmaceutics, namely to embodiments of a method for therapeutic treatment of Alzheimer's disease in an individual. In one embodiment, the method involves administering to an individual a therapeutic methylthioninium (MT)-containing compound LMTX of formula

,

(where H_nX is a protic acid, p = 1 or 2, n = 1 or 2, p × n = 2) for at least 2 months without concomitant administration of a neurotransmission-modifying compound, which is an acetylcholine or glutamate neurotransmitter activity modifier, and then performing the treatment with the LMTX compound with the concomitant introduction of said neurotransmission-modifying compound, wherein the individual has either not been previously treated with a neurotransmission-modifying compound, either performed, but canceled at least 3, 4, 5, 6, 7 or 8 weeks before the treatment with the LMTX compound. In another embodiment, the method is characterized by that an individual who has not responded to treatment with said neurotransmission-modifying compound is administered a compound LMTX, followed by treatment with a neurotransmission-modifying compound.

EFFECT: group of inventions provides a combination of two agents in a certain order and in certain groups of patients to enhance the effectiveness of treatment.

22 cl, 9 dwg, 3 tbl, 4 ex